Yüksel Ürün· @DrYukselUrun · X·· 2 天前评分70
正文 · 原文
Cisplatin-ineligible ≠ treatment-ineligible.
KEYNOTE-905: 2-year EFS 75.8% with EV/pembro vs 41% with surgery alone.
@myESMO @FAndreMD @curijoey @DrChoueiri @OncoAlert @OpenMedicineHQ #ESMO26
496 浏览 · 8 赞 · 4 转发 · 0 回复
会议摘要
4733O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905
https://esmocongress.esmo.orgNCT03924895NCT03924895按 - **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) 对上
- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
https://esmocongress.esmo.orgPerioperative EV + Pembro momentum by #DrAndersUllen in KEYNOTE-905 Ph.III ad hoc analysis of cis-ineligible MIBC. 2-yr EFS: 75.8% EV/Pembro vs 55.8% Pembro vs 41.0% surgery alone. EFS HR 0.40 vs 0.71 (each vs control). pCR 58.8% vs 25.3% vs 10.3%. #ESMO26 #BladderCancer @myESMO @OncoAlert在 X 查看被引用的帖子
来源：Yüksel Ürün · x.com